Oncolytics Biotech Inc. Announces Approval of US 40-F Registration
(CCN Disclosure)..., and when activated, may account for a large proportion of all human tumors.......Oncolytics researchers demonstrated that the reovirus was selectively able to kill cancer cells with this particular activation and successfully demonstrated that the virus could kill human cancer cells in vitro derived from breast, prostate, pancreatic and brain tumors, as well as being able to treat tumors successfully in a number of animal models....- Jan 23 6:04 AM ET
IF the story does not appear below, Click HERE to view the text of the story!
Note: The original website is displayed below - we have no control over it and are not responsible for the content of it, we just report it! IF you click on anything below, it will take you off of our website!
Original Source: http://biz.yahoo.com/ccn/010123/b.html
(Everything below this line is from VirtualTrials.com!)
Click HERE to return to brain tumor news headlines